Author:
Cho, H-J 1; Park, A 2; Park, M-N 2; Lee, E 1; Yoon, J 1; Suh, N 2; Park, H 2; Oh, Y-M 3; Yu, J 1
Author address:
1 Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; 2 Asan Institute for Life Sciences and University of Ulsan College of Medicine, Seoul, Korea; 3 Department of Pulmonary and Critical Care Medicine, Clinical Research Center for Chronic Obstructive Airway
Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Full conference title:
European Academy of Allergy and Clinical Immunology Congress 2016
Date: 5 August 2020
Abstract:
Background: Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease. Mesenchymal stem cells have been known to have an immunomodulatory effect. There is little information about the effect of MSC on the treatment of atopic dermatitis.
Method: We applied Aspergillus fumigatus (Af) extract (40 lg) to the dorsal skin of BALB/c mice 5 times a week repeatedly with an interval of 2 weeks to induce atopic dermatitis-like skin lesions. Umbilical cord derived mesenchymal stem cells (UCMSCs) (2 9 107 /ml) were injected subcutaneously at the last day of Af application. Clinical score and transepidermal water loss (TEWL) were assessed and histology was examined at 1, 5, and 10 days after injection of UC-MSCs. To evaluate a dosedependent effect, UC-MSCs of 4 x 107 /ml were also injected.
Results: The clinical score and TEWL were decreased at 5 days after subcutaneous injection of UC-MSCs. Moreover, UC-MSCs inhibited eosinophilic infiltration in skin lesions, and decreased the levels of total IgE. However, the effects of UC-MSCs were not dose dependent.
Conclusion: UC-MSCs alleviated atopic dermatitis-skin lesion in a murine model, which suggests therapeutic potential of UC-MSCs for human atopic dermatitis.
Abstract Number: 591
Link to conference website:
Link Conference abstract:
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
ME Mead1*, PA de Castro2, JL Steenwyk1, M Hoenigl3, J Prattes3, R Rautemaa-Richardson4, CB Moore4, C Lass-Flörl5, JP Gangneux6, H Guegan6, N Van Rhinj4, A Rokas1, GH Goldman2, S Gago4
2022
43
-
v
RH Patil1,2*, I Kotta-Loizou3, A Palyzová1, T Pluháček1,2, R Coutts4, DA Stevens5,6, V Havlíček1,2
2022
42
-
v
A Martin-Vicente*, AV Nywening, X Guruceaga, H Thorn, J Xie, W Ge, JR Fortwendel
2022
41
-
v
DA Stevens1,2*, I Kotta-Loizou3, M Martinez1, RHA Coutts4, G Sass1
2022
39
-
v
AE Barber1,2*, T Sae-Ong3, K Kang3, B Seelbinder3, J Li4,5, G Walther6, G Panagiotou3,7, O Kurzai1,8
2022
38
-
v
E Bradshaw1, P Chandorkar2, E Hopwood3, E Kington3, MD Richardson2,3, R Rautemaa-Richardson2,3, L Novak Frazer2,3*
2022
37
-
v
SS Mojtahedi1*, H Zarrinfar2, MJ Najafzadeh3, M Bakhshaee4
2022
36
-
v
E Kashefi1, SJ Seyedi2, H Zarrinfar3*, AM Fata1, H Mehrad-Majd4, MJ Najafzadeh1
2022
35
-
v
SS Mojtahedi1, H Zarrinfar2*, MJ Najafzadeh3, M Bakhshaee4
2022
34